Cost-Effectiveness

The drumbeat of advice seems constant: countries must focus all efforts on suppressing the current COVID-19 coronavirus pandemic, regardless of expense or impact on the broader economy. But no country, no matter how wealthy, has unlimited resources to throw at this crisis.

Despite their intended use for rare diseases, so-called orphan drugs contribute substantially to prescription drug spending; in fact, it is estimated that in just two years’ time, orphan drugs will constitute more than 20 percent of the market for global pharmaceutical sales. Nowhere is t...

As countries strive to achieve the Sustainable Development Goals, including attaining and sustaining universal health coverage, decision-makers are increasingly using economic evaluation to drive macro policy choices and more granular technology-focused decisions. In a recent study, we discuss ...